Novogene Co., Ltd. (SHA:688315)
China
· Delayed Price · Currency is CNY 14.27
-0.15 (-1.04%)
At close: Mar 9, 2026
Novogene Market Cap
Novogene has a market cap or net worth of 5.78 billion as of March 9, 2026. Its market cap has decreased by -3.58% in one year.
Market Cap
5.78B
Enterprise Value
4.34B
Revenue
2.17B
Ranking
n/a
PE Ratio
33.13
Stock Price
14.27
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 5.78B, a decrease of -47.29%. That is a compound annual growth rate of -12.23%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 9, 2026 | 5.78B | 7.45% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Shouyao Holdings (Beijing) Co., LTD. | 5.86B |
| Kexing Biopharm | 5.97B |
| GemPharmatech | 6.05B |
| PharmaResources (Shanghai) | 5.64B |
| Xiangxue Pharmaceutical | 6.25B |
| R&G PharmaStudies | 6.30B |
| Hangzhou Biotest Biotech | 5.41B |
| Shanghai OPM Biosciences | 6.37B |